[神经内分泌癌的高剂量疗法与干细胞移植]

[High dosage therapy with stem cell transplantation in neuroendocrine carcinoma].

作者信息

Buxhofer V, Ruckser R, Kier P, Habertheuer K H, Zelenka P, Tatzreiter G, Dorner S, Vedovelli H, Sebesta C, Hinterberger W

机构信息

Ludwig Boltzmann-Institut für Stammzelltransplantation an der 2. Medizinischen Abteilung des Donauspitals im SMZ-Ost der Stadt Wien.

出版信息

Acta Med Austriaca Suppl. 2000;52:37-9.

PMID:11261277

Abstract

Neuroendocrine carcinoma and small-cell lung cancer (SCLC) are highly responsive to chemo- and radiotherapy. Nevertheless, most patients (pts.) experience relapse. At the 2nd department of medicine in the Donauspital, 4 pts. with neuroendocrine carcinomas of different primary sites underwent high-dose chemotherapy with autologous stem-cell transplantation (ASTx). Pt. 1 suffered from neuroendocrine lung cancer, pt. 2 from a small-cell carcinoma of the pancreas. Pt. 3 had a metastatic small-cell abdominal bulky tumor and pt. 4 presented with neuroendocrine carcinoma of the prostate. After 4-6 cycles induction chemotherapy pts. were consolidated with 1 cycle of HDCht and ASTx. Prior to HDCht pt. 1 and pt. 2 were in complete remission (CR) and pt. 3 and pt. 4 in partial remission. Pt. 3 converted in CR after HDCht. He is still in CR with a disease-free survival of 23 month after ASTx and 30 month after diagnosis. Pt. 1, 2 and 4 died from relapse 10, 16 and 5 month after ASTx and 16, 22 and 9 month after diagnosis. Pts. with neuroendocrine carcinomas might be suitable candidates for HDCht and ASTx.

摘要

神经内分泌癌和小细胞肺癌（SCLC）对化疗和放疗高度敏感。然而，大多数患者会复发。在多瑙医院第二内科，4例不同原发部位的神经内分泌癌患者接受了高剂量化疗及自体干细胞移植（ASTx）。患者1患有神经内分泌肺癌，患者2患有胰腺小细胞癌。患者3有转移性小细胞腹部巨大肿瘤，患者4患有前列腺神经内分泌癌。在进行4 - 6周期诱导化疗后，患者接受1周期的高剂量化疗及自体干细胞移植巩固治疗。在高剂量化疗前，患者1和患者2处于完全缓解（CR）状态，患者3和患者4处于部分缓解状态。患者3在高剂量化疗后转为完全缓解。他仍处于完全缓解状态，自体干细胞移植后无病生存期为23个月，诊断后为30个月。患者1、2和4分别在自体干细胞移植后10、16和5个月以及诊断后16、22和9个月死于复发。神经内分泌癌患者可能是高剂量化疗及自体干细胞移植的合适候选者。